CD79B and B-cell non-Hodgkin lymphoma: Neutropenia is more consistently observed in ADCs that contain a MMAE payload [21], including brentuximab vedotin [22], and was recently identified as a key toxicity of polatuzumab vedotin, a CD79b-targeting ADC, as part of a dose-escalation study in B-cell NHL patients [23].